Functional impairment of human resident cardiac stem cells by the cardiotoxic Antineoplastic agent trastuzumab

Stem Cells Translational Medicine

Volumn 1, Issue 4, 2012, Pages 289-297

  Barth, Andreas S ^a   Zhang, Yiqiang ^b   Li, Taosheng ^b   Smith, Rachel R ^b   Chimenti, Isotta ^b   Terrovitis, Ioannis ^b   Davis, Darryl R ^b   Kizana, Eddy ^b   Ho, Alice S ^c   Brian, O'Rourke ^a   Wolff, C Antonio ^d   Gerstenblith, Gary ^a   Marbán, Eduardo ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c Johns Hopkins University   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Adult stem cells; Angiogenesis; Cardiac; Chemotherapy

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CD31 ANTIGEN; CD34 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR TBX5; TRASTUZUMAB; TROPOMYOSIN; TROPONIN I; ANTINEOPLASTIC AGENT; CARDIOTOXIN; ERBB2 PROTEIN, HUMAN; MESSENGER RNA; MONOCLONAL ANTIBODY; MUSCLE PROTEIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAPILLARY DENSITY; CARDIOTOXICITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSPLANTATION; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FLOW CYTOMETRY; HEART EJECTION FRACTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE BIOPSY; HEART MUSCLE CELL; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCAR; STEM CELL; ANIMAL; BIOSYNTHESIS; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; HEART MUSCLE; METABOLISM; MOUSE MUTANT; PATHOLOGY; REGENERATION; STEM CELL TRANSPLANTATION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARDIOTOXINS; CELL DIFFERENTIATION; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MICE; MICE, SCID; MUSCLE PROTEINS; MYOCARDIAL INFARCTION; MYOCARDIUM; RECEPTOR, ERBB-2; REGENERATION; RNA, MESSENGER; STEM CELL TRANSPLANTATION; STEM CELLS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84873712445     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2011-0016     Document Type: Article

References (47)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.
3. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684.
4. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792.
5. Seidman A, Hudis C, Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215-1221.
6. Li TS, Cheng K, Lee ST et al. Cardiospheres recapitulate a niche-like microenvironment rich in stemness and cell-matrix interactions, rationalizing their enhanced functional potency for myocardial repair. STEM CELLS 2010; 28:2088-2098.
7. Messina E, De Angelis L, Frati G et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res 2004; 95:911-921.
8. Smith RR, Barile L, Cho HC et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 2007;115:896-908.
9. Chimenti I, Smith RR, Li TS et al. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circ Res 2010;106:971-980.
10. Takehara N, Tsutsumi Y, Tateishi K et al. Controlled delivery of basic fibroblast growth factor promotes human cardiosphere-derived cell engraftment to enhance cardiac repair for chronic myocardial infarction. J Am Coll Cardiol 2008;52:1858-1865.
11. Tang YL, Zhu W, Cheng M et al. Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. Circ Res 2009;104:1209-1216.
12. Davis DR, Zhang Y, Smith RR et al. Validation of the cardiosphere method to culture cardiac progenitor cells from myocardial tissue. PLoS One 2009;4:e7195.
13. 2+ exchanger report cardiogenic differentiation in stem cells. Mol Ther 2008;16: 957-964.
14. du Manoir JM, Francia G, Man S et al. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res 2006;12:904-916.
15. Sadek H, Hannack B, Choe E et al. Cardiogenic small molecules that enhance myocardial repair by stem cells. Proc Natl Acad Sci USA 2008;105:6063-6068.
16. Takagawa J, Zhang Y, Wong ML et al. Myocardial infarct size measurement in the mouse chronic infarction model: Comparison of area-and length-based approaches. J Appl Physiol 2007;102:2104-2111.
17. Seeger FH, Tonn T, Krzossok N et al. Cell isolation procedures matter: A comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur Heart J 2007;28:766-772.
18. Davis DR, Kizana E, Terrovitis J et al. Isolation and expansion of functionally-competent cardiac progenitor cells directly from heart biopsies. J Mol Cell Cardiol 2010;49:312-321.
19. Davis DR, Ruckdeschel Smith R, Marban E. Human cardiospheres are a source of stem cells with cardiomyogenic potential. STEM CELLS 2010;28:903-904.
20. Johnston PV, Sasano T, Mills K et al. Engraftment, differentiation, and functional benefits of autologous cardiosphere-derived cells in porcine ischemic cardiomyopathy. Circulation 2009;120:1075-1083.
21. Tang XL, Rokosh G, Sanganalmath SK et al. Intracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day-old infarction. Circulation 2010;121:293-305.
22. Zakharova L, Mastroeni D, Mutlu N et al. Transplantation of cardiac progenitor cell sheet onto infarcted heart promotes cardiogenesis and improves function. Cardiovasc Res 2010;87:40-49.
23. Terrovitis J, Lautamaki R, Bonios M et al. Noninvasive quantification and optimization of acute cell retention by in vivo positron emission tomography after intramyocardial cardiac-derived stem cell delivery. J Am Coll Cardiol 2009;54:1619-1626.
24. Procter M, Suter TM, de Azambuja E et al. Longer-term assessment of trastuzumabrelated cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 2010;28: 3422-3428.
25. Russell SD, Blackwell KL, Lawrence J et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: A combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 2010;28:3416-3421.
26. Guarneri V, Lenihan DJ, Valero V et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The M.D. Anderson Cancer Center experience. J Clin Oncol 2006;24:4107-4115.
27. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility. J Clin Oncol 2007;25:3525-3533.
28. Gassmann M, Casagranda F, Orioli D et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 1995;378:390-394.
29. Lee KF, Simon H, Chen H et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995;378:394-398.
30. Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature 1995;378:386-390.
31. Zhao YY, Sawyer DR, Baliga RR et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 1998;273:10261-10269.
32. Ozcelik C, Erdmann B, Pilz B et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci USA 2002;99: 8880-8885.
33. Bergmann O, Bhardwaj RD, Bernard S et al. Evidence for cardiomyocyte renewal in humans. Science 2009;324:98-102.
34. Kajstura J, Urbanek K, Perl S et al. Cardiomyogenesis in the adult human heart. Circ Res 2010;107:305-315.
35. Beltrami AP, Barlucchi L, Torella D et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003; 114:763-776.
36. Oh H, Bradfute SB, Gallardo TD et al. Cardiac progenitor cells from adult myocardium: Homing, differentiation, and fusion after infarction. Proc Natl Acad Sci USA 2003; 100: 12313-12318.
37. Martin CM, Meeson AP, Robertson SM et al. Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart. Develop Biol 2004;265:262-275.
38. White AJ, Smith RR, Matsushita S, et al. Intrinsic cardiac origin of human cardiospherederived cells. Eur Heart J 2011 (in press).
39. Cheng K, Li TS, Malliaras K, et al. Magnetic targeting enhances engraftment and functional benefit of iron-labeled cardiosphere-derived cells in myocardial infarction. Circ Res 2010;106:1570-1581.
40. Bearzi C, Rota M, Hosoda T et al. Human cardiac stem cells. Proc Natl Acad Sci USA 2007; 104:14068-14073.
41. Sun M, Yan X, Bian Y et al. Improving murine embryonic stem cell differentiation into cardiomyocytes with neuregulin-1: Differential expression of microRNA. Am J Physiol Cell Physiol 2011;301:C21-C30.
42. Wang Z, Xu G, Wu Y et al. Neuregulin-1 enhances differentiation of cardiomyocytes from embryonic stem cells. Med Biol Eng Comput 2009;47:41-48.
43. Zhu WZ, Xie Y, Moyes KW et al. Neuregulin/ErbB signaling regulates cardiac subtype specification in differentiating human embryonic stem cells. Circ Res 2010;107:776-786.
44. Güler M, Yilmaz T, Ozercan I et al. The inhibitory effects of trastuzumab on corneal neovascularization. Am J Ophthalmol 2009; 147:703-708.e2.
45. Izumi Y, Xu L, et al.Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 2002;416:279-280.
46. Auerbach R, Lewis R, Shinners B et al. Angiogenesis assays: A critical overview. Clin Chem 2003;49:32-40.
47. Assmus B, Tonn T, Seeger FH et al. Red blood cell contamination of the final cell product impairs the efficacy of autologous bone marrow mononuclear cell therapy. J Am Coll Cardiol 2010;55:1385-1394.